Welcome to article directory Fosamax Side Effects. Here You can find interesting and useful information on most popular themes.

There are 90 published articles and 1 registered authors in our article directory.

Recent Articles

Paxil Lawsuit Info Discovery

Paxil Lawsuit News – 5/14/2012: If you were prescribed Paxil and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Paxil Lawsuit: There are believed to be adverse effects of Paxil for infants of mothers who continue to take their Paxil medication during their first trimester. Infants who are exposed to Paxil may be at a higher risk for developing congenital malformations, particularly cardiovascular malformations. Paxil is believed to cause more birth defects in infants than other SSRIs. It is recommended by doctors and other healthcare professionals that women should discontinue the use of the antidepressant prior to conception as well as stop using Paxil while pregnant. However, completely stopping Paxil after years of treatment is easier said than done. Doctors are additionally concerned about how the potential untreated depression can affect the developing fetus in the womb. It is important to review the health issues that women and their infants face when considering Paxil and pregnancy. Studies have suggested that women who took Paxil exhibited a sevenfold increase in the risk for developing some types of cancer.

Other side effects of Paxil are cranial birth defects. GlaxoSmithKline also sent out a letter to healthcare professionals about the risk of cranial birth defects. The letter alerted the doctors that exposure to Paxil is associated with this type of birth defect. This defect is characterized by the premature closing of one or more of the fibrous joints between the bones of the skull before brain growth is complete. Dangerous adverse effects of Paxil while pregnant can cause persistent pulmonary hypertension (PPHN). Concerning PPHN, there was an FDA warning for Paxil users stating that when babies are exposed to SSRIs while in the womb, they are at an elevated risk for developing the disorder. Heart birth defects are another side effect. The FDA issued a Paxil warning that suggested when women take Paxil during their first trimester, the baby is at a significantly higher risk for developing a heart birth defect more so than any other antidepressant.

Paxil News: Additional Information and Resources

Paxil Lawsuit: A side effect of Paxil that definitely warrants concern is if you develop suicidal thoughts and behaviors. In addition, other side effects from Paxil include changes in your mood or behavior, anxiety and/or panic attacks, change in sleeping patterns, mania (mental and/or physical hyperactivity), impulsivity, irritability, agitation, hostility and even aggressiveness. With any of these side effects, it is important to contact your doctor immediately. There are also some adverse effects of Paxil that require immediate medical attention. You will need to get emergency medical help if you show any signs of an allergic reaction. For example, if you begin to notice a skin rash or hives, difficulty breathing, swelling of your face, swelling of your lips, or swelling of the tongue or throat, contact a doctor immediately.

Paxil bad side effects include a possibility for increased thoughts of suicide when first beginning the antidepressant. This possibility is increased even more if you are younger than 24 years old. You will need to visit a doctor regularly for at least the first twelve weeks of treatment. Of course, increased suicidal thoughts and behavior are side effects that you definitely want to prevent. However, if you experience any of the other side effects from Paxil, contact a doctor immediately. They are as follows: mood or behavior changes, increased anxiety, panic attacks, trouble sleeping, if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), or more depressed than when first starting the medication. Unfortunately, there are even more side effects to Paxil. Paxil has the possibility to cause heart defects and serious, life-threatening lung problems in newborn babies whose mothers take the medication during pregnancy. So, taking Paxil while pregnant should definitely be strongly considered before starting the medication.

Our use of the term or terms Paxil Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Paxil Lawsuit visit our site often.

Posted in Paxil Lawsuit | Tagged |

Paxil Lawsuit

Paxil Lawsuit News – 5/10/2012: Please contact us today if you took Paxil Lawsuit and suffered unusual side effects or other injuries.

Paxil Lawsuit: The U.S. Food and Drug Administration (FDA) has examined the relationship between Paxil and pregnancy. Paxil, manufactured by GlaxoSmithKline, is an antidepressant drug known to be a selective serotonin reuptake inhibitor (SSRI). It was approved by the FDA to treat depression and several other psychiatric disorders. Studies have been conducted that included women who took Paxil while pregnant. The results indicated women who took the antidepressant drug during pregnancy were at an elevated risk for having a child born with a Paxil birth defect. In addition to birth defects, there are some other serious side effects of Paxil. These include mania, where individuals may become hyperactive, excitable, or elated, seizures, bleeding problems and sexual problems.

Paxil birth defects have led to people filing lawsuits against Paxil. In October 2009, GlaxoSmithKline was ordered by a Philadelphia court to pay a $2.5 million settlement in a suit claiming Paxil caused heart defects in a 3-year old boy. The boy in question was born with some serious alleged Paxil birth defects such as heart defects which threatened his life. According to the boy’s mother, it was because she took Paxil during pregnancy. During the case, the plaintiff’s attorneys claimed that in 1993 GlaxoSmithKline destroyed raw data from animal studies and in 1996, 1998 and 2000, safety reports were withheld concerning the adverse effects of Paxil. This $2.5 million settlement was the first verdict in more than 600 cases filed alleging GlaxoSmithKline knew the risks associated with being pregnant on Paxil and hid the risks to boost its profits. More Paxil lawsuits are being filed each month by mothers who took Paxil while pregnant prior to the Paxil warning issued in 2005. It may take years for the Paxil litigation to be resolved and GlaxoSmithKline may have to pay millions to fully resolve the issues.

If you or a loved one has experienced serious side effects from Paxil, you should contact a Paxil birth defects lawyer. They will be able to evaluate your claim and give you information on all your legal rights.

Our use of the term or terms Paxil Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Paxil Lawsuit visit our site often.

Posted in Paxil Lawsuit | Tagged |

Yaz Lawsuit Process

Yaz Lawsuit News – 5/9/2012: If you were prescribed Yaz and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Yaz Lawsuit: This drug is generating a growing number of Yaz Lawsuits by individuals who believe it may be the cause of their Yaz Blood Clots. A Safety Review has been released by the U.S. Food and Drug Administration (FDA) regarding contraceptives containing drospirenone and the possible increased risk of Yaz Blood Clots which could lead to stroke, heart attacks, pulmonary embolism and deep vein thrombosis. If you call Best Legal Source at 800-611-7080 or complete the contact information to the right, we will connect you with a Yaz Lawsuit attorney who will discuss your concerns and inform you of your legal options regarding the filing of a Yaz Lawsuit.

Yaz Lawsuits, Yaz Lawsuit and Yaz Lawsuit attorneys are general terms used to describe the legal process provided by an attorney experienced in pharmaceutical litigation. Yaz Blood Clots and any other phrase containing the word Yaz are used descriptively and do not imply any relationship between the manufacturers of Yaz and Best Legal Source.

Yaz Lawsuit News: More information about your search

Yaz Lawsuit: The Best Legal Source Yaz Lawsuit website is intended for injured parties who believe their injuries were directly related to using the drug Yaz. It was created to assist these individuals in finding a Yaz Lawsuit attorney willing to take their case. If you have developed Yaz Blood Clots while taking the medication Yaz, let Best Legal Source put you in touch with a knowledgeable group of Yaz Lawsuit attorneys.

Our use of the term or terms Yaz Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Yaz Lawsuit visit our site often.

Posted in Yaz Lawsuit | Tagged |

Yaz Lawsuit Action

Yaz Lawsuit News – 5/8/2012: Yaz may be linked to serious negative side effects. If you took Yaz and believe you suffered negative side effects as a result, contact us today so that we can make arrangements for a free consultation with a law firm that is investigating cases related to the side effects of Yaz.

Yaz Lawsuit: Injured parties may discover that a Yaz Lawyer can give them the resources to receive compensation for damages related to Yaz. A Yaz Lawyer knows the risks of this birth control. Side effects include blood clots which could lead to a stroke, heart attack, deep vein thrombosis or pulmonary embolism. When attempting to pursue complicated litigation, it is best to go through a Yaz Lawyer who can give you professional help. Best Legal Source will get you connected with a Yaz Lawyer if you will call (800) 611-7080 or complete the evaluation form to your right.

Has your health been jeopardized after taking Yaz?  You can start a conversation with a Yaz Lawyer regarding a lawsuit. The FDA has released several safety reviews regarding the possibility of increasing your risk of blood clots if you are taking Yaz or another drospirenone-containing birth control pill. The process of talking to your personal Yaz Lawyer begins by filling out the form to your right, or by calling Best Legal Source at the number above. We’ll put you in touch with a Yaz Lawyer qualified to handle your lawsuit.

Yaz Lawsuit News: More information about your search

Yaz Lawsuit: Yaz Lawyer and Yaz Lawyers are used to illustrate the employees filing lawsuits against Yaz. Yaz Lawyer is a broad term used to describe those taking on these specific cases.  The use of the phrase Yaz Lawyer is for illustrative purposes only. Best Legal Source will have an experienced Yaz Lawyer contact you in reference to your Yaz lawsuit. Lawsuits have a narrow window in which to be filed so the time is now to start discussions with your Yaz Lawyer. Call today and regain control of your life.

Our use of the term or terms Yaz Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Yaz Lawsuit visit our site often.

Posted in Yaz Lawsuit | Tagged |

Actos Lawsuit Report

Actos Lawsuit News – 5/3/2012: Did you take Actos? Please contact us today if you took Actos and later experienced harmful side effects. We will connect you with a lawyer that is experienced in complex litigation that may be able to help you recover monetary damages.

Actos Lawsuit: The United States Food and Drug Administration issued a Safety Announcement on June 15th 2011 warning the public about a link between the drug Actos and Bladder Cancer. This warning has led to the investigation of a new Actos Lawsuit by attorneys across the United States. This is not the first type of Actos Lawsuit that has been investigated and filed on behalf of people who have been injured by the use of Actos. This latest Actos Lawsuit centers around the link between Actos and Bladder Cancer. If you took Actos and later developed Bladder Cancer please contact us today so that we can make arrangements for a free consultation with an Actos Attorney regarding your potential Actos Lawsuit.

CT Scan or CAT (computerized axial tomography) provides a computerized cross sectional visualization of the abdomen and pelvis. X ray images are synthesized into exquisitely detailed images. The CT scan can be done with or without IV contrast, and therefore has the same limitations as IVP in those with allergies to contrast or renal insufficiency. These studies are excellent for finding renal cell cancers and stones within the kidneys and ureter, but not very good at delineating cancers of the lining. CT scan is often an important part of staging bladder cancer, determining whether the cancer has spread.

Magnetic Resonance Imaging (MRI) is a technology which uses strong magnets to provide detailed images of your internal organs. Like ultrasound, this study has no known harmful effects on the body. It does not require contrast injection like CT scan and can be done safely in patients with renal insufficiency. It is not generally used for initial screening. Many individuals find the test uncomfortable due to a loud noise heard throughout the test, in addition to the close quarters the machine requires, leading to feelings of claustrophobia. A mild sedative may be required if the test is necessary and the individual experiences these uncomfortable feelings.

Actos Lawsuit News: More information about your search

Actos Lawsuit: Initial treatment may eradicate an individual’s bladder cancer, however, for many, recurrent tumors may develop. Up to 70% of individuals will have recurrent bladder cancer after initial therapy. In approximately one third of patients, not only will tumors recur, but they will become more serious over time, developing a higher grade or stage. This chapter will review the importance of staging bladder cancer, the single most important predictor of future problems. In addition, we will review other important indicators that impact the prognosis.

After the diagnosis of cancer is made, it is critical to establish the stage of the cancer. Cancer stage quantifies the extent of cancer in the individual. The number of tumors, their size, whether or not they have grown into the wall of the organ or spread beyond, all fit into the various stages of a particular cancer. Most cancers can be found at an early, nonlethal stage. As they grow and worsen, they can invade the wall of the organ they lodge in, spread locally through the organ into surrounding tissue, or spread throughout the body via the lymphatic or blood system.

In the case of bladder cancer, initial stage is critical in predicting the prognosis. For individuals with bladder cancer, recurrence (repeated tumors) is common. For many, progression (the development of higher grade, invasive or metastatic cancer) is also a real concern. By looking at the initial stage of the bladder cancer and restaging with each new cancer recurrence, the urologist can predict or prognosticate the possibility of the individual developing more life threatening invasive disease which has the ability to spread beyond the bladder and lead to death. Treatment options exist at each stage of cancer. It is the goal of the urologist to preserve your bladder as long as possible without jeopardizing your life with a cancer that may spread and become incurable.

Actos Lawsuit News: Additional Information and Resources

Actos Lawsuit: There is a very close relationship between survival of an individual and the stage of bladder cancer at diagnosis. For superficial disease, five year survival rates are greater than 90%. Once the cancer has spread into the bladder muscle and beyond, survival is markedly reduced. Five year survival in those with T2 disease (tumor invading superficial bladder muscle) is 60-75%, T3 disease (tumor invading deep muscle) 36-58%, and for those with T4 disease (tumor invading surrounding organs) or with node positive disease, 4-35%.’ With distant (metastatic) spread, survival at five years is less than 5%.

Most individuals with bladder cancer will undergo an initial removal of their bladder tumor by biopsy or for larger tumors by resection of their tumor via a resectoscope. For complete details see Chapter 8. Once this tumor is removed, the pathologist will determine and report on the extent of tumor invasion into the wall of the bladder. If the tumor has grown into the prostate, tissue removal via the resectoscope from this location will also be reviewed and reported pathologically. This pathologic diagnosis determines the initial stage of the cancer.

When dealing with large tumors after the initial cancer resection, your urologist may do a manual exam under anesthesia. By pressing deeply on the pelvis, the urologist may be able to palpate the tumor and assess its possible spread beyond the bladder. With modern technology and the availability of the CT scan, the manual exam is now of less importance. The CT scan can often visualize a thickened or distorted bladder wall, indicating the possibility of tumor involvement or extension through the wall. More importantly, it can determine spread to adjacent organs or lymph node involvement. Distant spread into the abdomen or beyond may also be seen. Other studies, such as the Bone Scan or Chest X ray can assess the presence and extent of metastatic diseases, MRI can be used for those with limited kidney function that cannot have a CT scan. More recently, Positron Emission Tomography (PET) scan has become available. This study can sometimes locate small deposits of metastatic disease not visible on CT or MRI scan.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

Posted in Actos Lawsuit | Tagged |

Januvia Attorneys

Januvia Attorneys News – 5/2/2012: Did you take Januvia? Please contact us today if you took Januvia and later experienced harmful side effects. We will connect you with a lawyer that is experienced in complex litigation that may be able to help you recover monetary damages.

Januvia Attorneys: As long as a nest of tumor cells remains small—less than a millimeter in diameter—it can depend on diffusion to solve its logistical problems of supply and elimination. Mol­ecules released by die cancer cell or its normal neighbors can diffuse over this short distance quite effectively. But once the clump of cells reaches die one millimeter size, it bumps up against a limit, a glass ceiling. Now the process of diffusion can no longer provide an adequate flow of nutrients and oxygen and a rapid removal of wastes. Soon, cells within the clump become starved and begin to choke on their own wastes. Such anoxic cells often die from mediated apoptosis.

The death rate of these cells from asphyxiation and meta­bolic poisoning begins to approach the rate at which these cells can regenerate themselves. Any gains made through cell proliferation are neutralized by attrition, and so the size of this tumor cell clump remains constant. Some microscopic nests of tumor cells may remain in this static state for years, possibly even decades. To become threatening, these nests of tumor cells must break out of their futile cycles of division followed by starva­tion and asphyxiation. Such escape demands that the cells within these nests become truly creative: They must invent a better way of accessing nutrients and voiding wastes.

Their solution lies in developing their own blood circulation system. While the small band of tumor cells has sur­vived half-starved, its normal neighbors nearby have all along enjoyed a reliable supply of nourishment and oxygen because of their close connections with die body’s circula­tory system. Unlike the small nest of tumor cells, normal tissue is interlaced with a dense network of capillaries. Often the array of capillaries is so dense that every cell in a tissue has direct access to an adjacent capillary. These small ves­sels, just wide enough to allow red blood cells to pass in sin­gle file, supply all metabolically active tissues throughout the body and carry off their wastes.

To grow beyond the one-millimeter limit, a nest of cancer cells must invent a way to recruit capillaries into its midst. A surgeon in Boston, has spent the past two decades uncovering the cancer cells’ strategy. Some cells in the clump, aping the normal cells around them, acquire the ability to secrete growth factors that attract endothelial cells from nearby tissue and induce these cells to multiply. Capillaries grow into the clump of cancer cells. Finally, the tumor cell clump has acquired direct access to oxygen- and nutrient-rich blood. Now this nest of cells can take off. Their proliferative agenda, frustrated for so many years, can now be fulfilled. Their numbers begin to increase explosively.

Januvia Attorneys News: More information about your search

Januvia Attorneys: The growth factors released by these cancer cells are often called “angiogenic factors” because they encourage angio-genesis, the construction of blood vessels. These factors in­clude VEGF and bFGF (basic fibroblast growth factor). The eventual success of the nest of tumor cells is closely tied to its ability to induce angiogenesis. Should members of this clump begin to elaborate high levels of angiogenic factors, their descendants, months later, will form tumors that are densely interlaced with capillaries; these cancers are often destined to grow aggressively and spread widely. Tumors that have poorly developed capillary networks are more in­dolent, and patients carrying such tumors usually have a much better prognosis. Indeed, some physicians use the presence or absence of dense capillary networks in tumor samples to determine the stage of tumor development and to predict its future course.

A tumor mass one centimeter in diameter may contain as many as a billion cells. At first glance, the number seems huge, but it pales next to the number of cells in the body as whole—more than ten thousand times more. So a cancer this size is rarely life-threatening. In most places in the body, it probably will not compromise die functioning of a vital organ. Most tumors need to be far larger before they become lethal. Of those patients who succumb to cancer, fewer than 10 percent die from tumors that continue to grow at the same site where they originally took root. In the great majority of cases, die killers are the metastases—colonies of cancer cells that have left the site of the original, primary tumor and have settled elsewhere in the body. It is these migrants, or rather the new tumors that they seed, that usually cause death.

Januvia Attorneys News: Additional Information and Resources

Januvia Attorneys: The major insight afforded by this revolution is that can­cer is a disease of damaged genes. We now know the identi­ties of many of the culprit genes—oncogenes and tumor suppressor genes. They control the behavior of the cells in which they operate; the cells respond in turn by generating tumors. To be sure, many cancer-related genes still remain to be identified and isolated by gene cloning. The means by which many genes influence cell behavior also remain to be discovered. We know that the agents that provoke human cancer pro­mote, directly or indirectly, the creation of mutant genes. We know that the appearance of a human tumor requires a succession of mutations, each responsible for perturbing a distinct cellular growth-controlling gene. And we know that processes that threaten the integrity of the cell genome, including defects in its maintenance and repair, strongly influ­ence the rate at which cancers appear.

The discovery of various growth-controlling genes has provided us with a view of the complex decision-making circuitry that lies within each human cell. Biologists have cataloged the diverse behaviors of cells for more than a century. Cell behavior seemed to have its own logic, determined by submicroscopic vital forces hidden deep within. We now understand that logic in terms of critical signal-processing pro­teins that determine the cell’s responses to a wide variety of stimuli; these proteins assemble to form an elaborate signal­ processing circuitry. Every week new pieces are added to the wiring diagram of this circuitry. Its design—its interconnections and the actions of its component parts—determines how cells behave. Knowledge of this circuitry will provide the ultimate answers for those interested in understanding cancer. There are no deeper or more subtle mechanisms hiding in some secret corner of the cell. The answers are all there, or will be found there shortly. Two decades ago, we knew nothing of all this.

Major reductions in cancer mortality will derive from identifying and eliminating discrete causes of the disease— in particular, certain aspects of diet and lifestyle. Much of this job is the purview of the epidemiologists. Indeed, we have already learned much from them. They have framed the problem, defined its scope, breadth, and depth. They also have disabused us of a couple of notions widespread in some circles: that the industrialized West is being inundated with a cancer epidemic, and that most of this inundation is traceable to chemical pollutants in the air and in the food chain. Almost all cancer deaths in the United States were caused by tobacco. The obvious response—reduction in tobacco usage—has already shown its effectiveness: By 1990, the century-long increase in lung cancer death rose in men was reversed. Without the contribution of lung cancer, the overall age-adjusted death rate from cancer would have declined 14 percent between 1950 and 1990.of this age-adjusted increase in cancer deaths flows directly from tobacco consumption.

Our use of the term or terms Januvia Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Januvia Attorneys News visit our site often.

Posted in Januvia Attorneys | Tagged |

Byetta Attorneys Report

Byetta Attorneys News – 5/2/2012: Byetta may be linked to serious negative side effects. If you took Byetta and believe you suffered negative side effects as a result, contact us today so that we can make arrangements for a free consultation with a law firm that is investigating cases related to the side effects of Byetta.

Byetta Attorneys: The explosive growth of genetics in the twentieth century showed that all organisms, including even simple single-cell organisms such as bacteria and baker’s yeast, rely on genes as the templates for making progeny. Also, virtually all organ­isms, ranging from bacteria to humans, were found to have evolved elaborate mating mechanisms. In every case, the same underlying motive was apparent: Mating enabled the exchange and mixing of genes between members of a species. Since all species comprised populations of genetically heterogeneous individuals, mating afforded the oppor­tunity of testing novel combinations of genes. Novel gene combinations might yield offspring that were more fit than their parents. That increased fitness, in turn, powered the engine of evolution.

Controlled mating of genetically distinct individuals be­came a powerful tool for studying the behavior of genes—in particular, how the genes carried by one parent in a mating blended with those of its partner. While bacteria and yeast cells were found to mate with one another, cells prepared from mammalian tissues lacked that ability. The only matings naturally allowed between mammalian cells involved the fusion of sperm and egg. These facts prevented re­searchers from observing the outcome of mating dissimilar kinds of cells—bone cells from one person with bone cells from another, or bone cells with muscle cells of the same person.

Under some conditions, these fusions could involve dozens of cells simultaneously, yielding enormous cells that were far too large and unwieldy to grow and divide. Far more interesting were the fusions involving only pairs of cells. Such two-cell hybrids could grow and divide, transmitting to offspring the pooled genes originating from the two parent cells. The outcome of these hybridizations seemed obvious. Cancer is a dominating force in the body, and tumor cells in­variably grow more vigorously than their normal counter­parts. Therefore, if a cancer cell was fused to a normal cell, the potent genes in the cancer cell would dominate over the weaker genes carried by its normal partner. The hybrid cell carrying both sets of genes should, by this logic, behave like the cancerous parent. Among other things, this hybrid cell should be able to seed tumors when injected into a mouse or rat.

The genes present in the normal cells seemed to be slowing down growth. They acted, in effect, like brakes that allowed cells to counteract any tendencies to lurch forward into runaway growth. Can­cer cells, having lost these genes, had lost their braking mechanism. Once the braking mechanism was reinstalled in the cancer cells by the cell hybridization trick, the cancer cells’ forward momentum ground to a lialt. Now these run­aways had a means of controlling the uncontrollable—their drive to grow without limit.

Byetta Attorneys News: More information about your search

Byetta Attorneys : Now there were two groups of genetic actors on the can­cer stage, each specifying a distinct part of the machinery that governed cell growth. The proto-oncogenes operated like the accelerator pedal in a car; mutant oncogenic versions of these genes seemed to result in pedals that were stuck to the floor. Conversely, the tumor suppressor genes worked like brakes. As normal cells developed into cancer cells, they might shed or inactivate these tumor suppressor genes, resulting in defective braking mechanisms. Runaway cell growth seemed to be explainable by either mechanism.

The existence of two diametrically opposite explanations of cancer formation demanded some resolution. Did some kinds of tumor cells rely on one mechanism to achieve ma­lignant growth while others used the alternative mechanism? Or did both mechanisms operate together within cancer cells? Perhaps stuck accelerators and faulty brakes conspired to create cancerous growth. The answers to these questions did not fall in place im­mediately. But the discovery of tumor suppressor genes did open the door to another aspect of human cancer—its heritability. Cancer often runs in families, and these genes provided an explanation for the origin of many kinds of familial cancer.

Byetta Attorneys News: Additional Information and Resources

Byetta Attorneys: But the most convenient and therefore most frequently used way for a cell to rid itself of a gene is more subtle. Most often, a gene will suffer only a single base change—a point mutation—in one of its sequences. Such a subtle change may have deadly consequences if it strikes a critical sequence in the gene. Point mutations may insert inappropriate punctua­tion marks into the middle of a gene; because these marks normally signal the end of a gene, they may terminate the read-out of the gene prematurely, causing truncation of the protein specified by this gene. Other times, the protein prod­uct of the gene may suffer some change in its string of amino acids that renders it nonfunctional. The result of all these mutations, large and small, will be the same: The cell will lose the services of the mutated gene.

In reality, losing the services of a tumor suppressor gene is more complicated than implied here. Almost all genes in our cells are present in two redundant copies, one deriving originally from our mother’s genes, the other from our father. In the case of tumor suppressor genes, this two-copy system offers a measure of protection to the cell. If one copy of a suppressor gene is accidental lost, the remaining gene copy serves as a perfectly adequate backup. Almost always, half a brake lining is as good as a whole one in slowing down cell growth.

Tumor cells usually resort to a more expedient way of eliminating the second copy of a tumor suppressor gene. Their strategy depends on the fact that the two partners in a human chromosome pair (such as the two thirteenth chromosomes, each of which carries an Rb gene copy) often line up next to one another in parallel array, look each other over, compare their respective DNA sequences, and then swap ge­netic information. One frequent result is that a gene se­quence present on one chromosome will now replace the corresponding sequence carried by its partner. Before this in­formation transfer, two distinct versions of a gene may have resided on the two paired chromosomes; afterward, one of these versions is lost, being replaced by a duplicated version of the gene originally present on the other chromosome. The result is two identical copies of a gene in a cell that previ­ously carried two dissimilar versions.

Our use of the term or terms Byetta Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Byetta Attorneys News visit our site often.

Posted in Byetta Attorneys | Tagged |

Byetta Class Action Top News

Byetta Class Action News – 5/2/2012: Did you take Byetta? Please contact us today if you took Byetta and later experienced harmful side effects. We will connect you with a lawyer that is experienced in complex litigation that may be able to help you recover monetary damages.

Byetta Class Action: Tumor cells usually resort to a more expedient way of eliminating the second copy of a tumor suppressor gene. Their strategy depends on the fact that the two partners in a human chromosome pair (such as the two thirteenth chro­mosomes, each of which carries an Rb gene copy) often line up next to one another in parallel array, look each other over, compare their respective DNA sequences, and then swap ge­netic information. One frequent result is that a gene sequence present on one chromosome will now replace the corresponding sequence carried by its partner. Before this information transfer, two distinct versions of a gene may have resided on the two paired chromosomes; afterward, one of these versions is lost, being replaced by a duplicated version of the gene originally present on the other chromosome.

Precancerous tumor cells on their way to becoming actively malignant will often use this trick to eliminate both copies of a tumor suppressor gene that has been holding back their growth. They will first mutate to inactivity one copy of the gene and then eliminate its partner through this loss-of-heterozygosity homogenization. Importantly, the chromosomal swaps that generate this homogenization often involve large regions of the chromosome surrounding the tu­mor suppressor gene, not just the gene itself. Hundreds of genes residing to the left and the right of the tumor suppres­sor gene on a chromosome will also become homogenized. Of course, the homogenization of neighboring gene copies is irrelevant for the growth of the developing tumor cells. These neighboring genes are nothing more than innocent by­standers. It is realty only the tumor suppressor gene that the tumor cell is intent on eliminating through use of the homog­enization trick.

Two things changed in modern times. We now live much longer than we used to. By the middle of the twentieth century, many of us began to live for seventy or eighty years, an age when this disease strikes frequently. A hundred years earlier, relatively few survived long enough to confront it. Our diet also changed from one heavy in grains and vegetables to fare that increasingly emphasized meat and large amounts of fat. The effects of diet are apparent from epidemiology: There are regions of Africa whose inhabitants follow a diet based al­most exclusively on vegetables and grains. These people run a risk of colon cancer that is less than one-tenth of that seen in the West.

Byetta Class Action News: More information about your search

Byetta Class Action: Some humans make these detoxifying enzymes at high levels, while others produce them at much lower levels. These differences, which are heritable, offer us the opportu­nity to understand the roles of these enzymes in protecting cells against attack by various carcinogens. For example, do individuals with low levels of these protective enzymes con­tract cancer more often than those having high levels? In fact, some striking differences have been uncovered. Smokers who make low levels of the NAT enzyme (N-acetyl transferase) run as much as two and a half times the risk of bladder cancer compared to smokers having high levels of the NAT enzyme. Low levels of a second detoxifying en­zyme, GSTMl (glutathione-S-transferase Ml), result in a threefold increase in the risk of lung cancer. These findings suggest that we may one day be able to calculate smokers’ risk of cancer based on their lifelong cigarette consumption and their levels of detoxifying enzymes.

Some mutagens succeed in penetrating this complex array of protective devices. Having escaped inactivation, these mutagens may proceed to react with and thereby damage the DNA molecules carried in the cell’s chromosomes. Every human cell sustains thousands of such mutagenic attacks every day. But in spite of this barrage, the cell’s DNA emerges at the end of the day relatively unscathed. This discrepancy demands explanation.

Close scrutiny of the machinery used by the cell to copy its DNA molecules reveals a similar discrepancy. The process by which cells replicate DNA in preparation for cell division is prone to error. Immediately after DNA poly­merase—the enzyme responsible for DNA replication—has copied a stretch of DNA, as many as one in every thousand bases of the newly made DNA strand may be incorrect, hav­ing been mistakenly inserted by the polymerase. But as be­fore, the actual rate at which mutations accumulate in the DNA is much lower. Somehow, the vast majority of these initial copying mistakes are not perpetuated in the DNA.

This dynamic has direct consequences for tumor forma­tion: If the DNA repair process fails, large numbers of altered bases will accumulate in a cell’s DNA. This means that the rate at which mutations accumulate is influenced by at least three distinct processes: damage inflicted on the DNA by mutagens of foreign or internal origin, mistakes made during DNA copying, and defects in die DNA repair machinery responsible for erasing the damage created by mutagens or miscopying. Since mutation is the engine that drives tumor progression, all three of these processes are likely to be involved in one way or another in causing cancer.

Byetta Class Action News: Additional Information and Resources

Byetta Class Action: Knowing about mutant genes allows us to trace the roots of cancer back to discrete, identifiable changes in the central controlling molecule of the cell, its DNA. But in one sense, these genetic discoveries are sterile and uninformative. Genes are pure information, nothing more than mathemati­cal abstractions. Studied in isolation, they tell us little about the real life of the cell. Moreover, the sequence of DNA bases that constitutes a gene usually reveals little about how this gene operates. So, even after we know that one or another gene is mutated during the development of a cancer, we still understand next to nothing about the mechanisms by which this mutant gene causes abnormal cell growth. Fortunately, molecular biology provides us with a useful train of logic that leads us toward an understanding of gene function. Genes instruct the cells around them to make specific pro­teins. It is the proteins that do the work of the genes. Proteins catalyze biochemical reactions or create elaborate physical structures. To understand how a gene works, we must know intimately how its protein functions.

In one sense, the roles played by the normal versions of oncoproteins are obvious: They help the normal cell regulate its growth. Unfortunately, this statement does not take us very far; it only restates the problem, and in a way that is not terribly useful. A more productive tack is suggested by the following question: Precisely how do normal cells know when to grow and when to hold back from growth? At any moment, the great majority of cells in our body are in a quiescent state. Only in tissues that renew themselves constantly, such as the colonic epithelium, the bone marrow (which generates new blood cells), and the skin, does one find large numbers of cells actively growing and dividing.

These dramatic differences in the proliferation rates of tissues bring us back to our question: Precisely how do any of these cells know when they should grow? The issue becomes even more complicated in the case of embryonic development, where cell proliferation results in the creation of new, complex tissues rather than the maintenance of an existing tissue architecture.

Our use of the term or terms Byetta Class Action is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Byetta Class Action News visit our site often.

Posted in Byetta Class Action | Tagged |

Januvia Attorney

Januvia Attorney News – 5/2/2012: If you were prescribed Januvia and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Januvia Attorney: As long as a nest of tumor cells remains small—less than a millimeter in diameter—it can depend on diffusion to solve its logistical problems of supply and elimination. Mol­ecules released by die cancer cell or its normal neighbors can diffuse over this short distance quite effectively. But once the clump of cells reaches die one millimeter size, it bumps up against a limit, a glass ceiling. Now the process of diffusion can no longer provide an adequate flow of nutrients and oxygen and a rapid removal of wastes. Soon, cells within the clump become starved and begin to choke on their own wastes. Such anoxic cells often die from mediated apoptosis.
The death rate of these cells from asphyxiation and meta­bolic poisoning begins to approach the rate at which these cells can regenerate themselves. Any gains made through cell proliferation are neutralized by attrition, and so the size of this tumor cell clump remains constant. Some microscopic nests of tumor cells may remain in this static state for years, possibly even decades. To become threatening, these nests of tumor cells must break out of their futile cycles of division followed by starva­tion and asphyxiation. Such escape demands that the cells within these nests become truly creative: They must invent a better way of accessing nutrients and voiding wastes.

Their solution lies in developing their own blood circula­tion system. While the small band of tumor cells has sur­vived half-starved, its normal neighbors nearby have all along enjoyed a reliable supply of nourishment and oxygen because of their close connections with die body’s circula­tory system. Unlike the small nest of tumor cells, normal tissue is interlaced with a dense network of capillaries. Often the array of capillaries is so dense that every cell in a tissue has direct access to an adjacent capillary. These small ves­sels, just wide enough to allow red blood cells to pass in sin­gle file, supply all metabolically active tissues throughout the body and carry off their wastes.

To grow beyond the one-millimeter limit, a nest of cancer cells must invent a way to recruit capillaries into its midst. A surgeon in Boston, has spent the past two decades uncovering the cancer cells’ strategy. Some cells in the clump, aping the normal cells around them, acquire the ability to secrete growth factors that attract endothelial cells from nearby tissue and induce these cells to multiply. Capillaries grow into the clump of cancer cells. Finally, the tumor cell clump has acquired direct access to oxygen- and nutrient-rich blood. Now this nest of cells can take off. Their proliferative agenda, frustrated for so many years, can now be fulfilled. Their numbers begin to increase explosively.

Januvia Attorney News: More information about your search

Januvia Attorney: The growth factors released by these cancer cells are often called “angiogenic factors” because they encourage angio-genesis, the construction of blood vessels. These factors in­clude VEGF and bFGF (basic fibroblast growth factor). The eventual success of the nest of tumor cells is closely tied to its ability to induce angiogenesis. Should members of this clump begin to elaborate high levels of angiogenic factors, their descendants, months later, will form tumors that are densely interlaced with capillaries; these cancers are often destined to grow aggressively and spread widely. Tumors that have poorly developed capillary networks are more in­dolent, and patients carrying such tumors usually have a much better prognosis. Indeed, some physicians use the presence or absence of dense capillary networks in tumor samples to determine the stage of tumor development and to predict its future course.

A tumor mass one centimeter in diameter may contain as many as a billion cells. At first glance, the number seems huge, but it pales next to the number of cells in the body as whole—more than ten thousand times more. So a cancer this size is rarely life-threatening. In most places in the body, it probably will not compromise die functioning of a vital organ. Most tumors need to be far larger before they become lethal. Of those patients who succumb to cancer, fewer than 10 percent die from tumors that continue to grow at the same site where they originally took root. In the great majority of cases, die killers are the metastases—colonies of cancer cells that have left the site of the original, primary tumor and have settled elsewhere in the body. It is these migrants, or rather the new tumors that they seed, that usually cause death.

Januvia Attorney News: Additional Information and Resources

Januvia Attorney: The major insight afforded by this revolution is that can­cer is a disease of damaged genes. We now know the identi­ties of many of the culprit genes—oncogenes and tumor suppressor genes. They control the behavior of the cells in which they operate; the cells respond in turn by generating tumors. To be sure, many cancer-related genes still remain to be identified and isolated by gene cloning. The means by which many genes influence cell behavior also remain to be discovered. We know that the agents that provoke human cancer pro­mote, directly or indirectly, the creation of mutant genes. We know that the appearance of a human tumor requires a succession of mutations, each responsible for perturbing a distinct cellular growth-controlling gene. And we know that processes that threaten the integrity of the cell genome, including defects in its maintenance and repair, strongly influ­ence the rate at which cancers appear.

The discovery of various growth-controlling genes has provided us with a view of the complex decision-making circuitry that lies within each human cell. Biologists have cataloged the diverse behaviors of cells for more than a century. Cell behavior seemed to have its own logic, determined by submicroscopic vital forces hidden deep within. We now understand that logic in terms of critical signal-processing pro­teins that determine the cell’s responses to a wide variety of stimuli; these proteins assemble to form an elaborate signal­ processing circuitry. Every week new pieces are added to the wiring diagram of this circuitry. Its design—its interconnections and the actions of its component parts—determines how cells behave. Knowledge of this circuitry will provide the ultimate an­swers for those interested in understanding cancer. There are no deeper or more subtle mechanisms hiding in some secret corner of the cell. The answers are all there, or will be found there shortly. Two decades ago, we knew nothing of all this.

Major reductions in cancer mortality will derive from identifying and eliminating discrete causes of the disease— in particular, certain aspects of diet and lifestyle. Much of this job is the purview of the epidemiologists. Indeed, we have already learned much from them. They have framed the problem, defined its scope, breadth, and depth. They also have disabused us of a couple of notions widespread in some circles: that the industrialized West is being inundated with a cancer epidemic, and that most of this inundation is traceable to chemical pollutants in the air and in the food chain. Almost all cancer deaths in the United States were caused by tobacco. The obvious response—reduction in tobacco usage—has already shown its effectiveness: By 1990, the century-long increase in lung cancer death rose in men was reversed. Without the contribution of lung cancer, the overall age-adjusted death rate from cancer would have declined 14 percent between 1950 and 1990.of this age-adjusted increase in cancer deaths flows directly from tobacco consumption.

Our use of the term or terms Januvia Attorney is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Januvia Attorney News visit our site often.

Posted in Januvia Attorney | Tagged |

Byetta Attorneys

Byetta Attorneys News – 5/1/2012: Did you take Byetta? Please contact us today if you took Byetta and later experienced harmful side effects. We will connect you with a lawyer that is experienced in complex litigation that may be able to help you recover monetary damages.

Byetta Attorneys: The explosive growth of genetics in the twentieth century showed that all organisms, including even simple single-cell organisms such as bacteria and baker’s yeast, rely on genes as the templates for making progeny. Also, virtually all organ­isms, ranging from bacteria to humans, were found to have evolved elaborate mating mechanisms. In every case, the same underlying motive was apparent: Mating enabled the exchange and mixing of genes between members of a species. Since all species comprised populations of genetically heterogeneous individuals, mating afforded the oppor­tunity of testing novel combinations of genes. Novel gene combinations might yield offspring that were more fit than their parents. That increased fitness, in turn, powered the engine of evolution.

Controlled mating of genetically distinct individuals be­came a powerful tool for studying the behavior of genes—in particular, how the genes carried by one parent in a mating blended with those of its partner. While bacteria and yeast cells were found to mate with one another, cells prepared from mammalian tissues lacked that ability. The only matings naturally allowed between mammalian cells involved the fusion of sperm and egg. These facts prevented re­searchers from observing the outcome of mating dissimilar kinds of cells—bone cells from one person with bone cells from another, or bone cells with muscle cells of the same person.

Under some conditions, these fusions could involve dozens of cells simultaneously, yielding enormous cells that were far too large and unwieldy to grow and divide. Far more interesting were the fusions involving only pairs of cells. Such two-cell hybrids could grow and divide, transmitting to offspring the pooled genes originating from the two parent cells. The outcome of these hybridizations seemed obvious. Cancer is a dominating force in the body, and tumor cells in­variably grow more vigorously than their normal counter­parts. Therefore, if a cancer cell was fused to a normal cell, the potent genes in the cancer cell would dominate over the weaker genes carried by its normal partner. The hybrid cell carrying both sets of genes should, by this logic, behave like the cancerous parent. Among other things, this hybrid cell should be able to seed tumors when injected into a mouse or rat.

The genes present in the normal cells seemed to be slowing down growth. They acted, in effect, like brakes that allowed cells to counteract any tendencies to lurch forward into runaway growth. Can­cer cells, having lost these genes, had lost their braking mechanism. Once the braking mechanism was reinstalled in the cancer cells by the cell hybridization trick, the cancer cells’ forward momentum ground to a lialt. Now these run­aways had a means of controlling the uncontrollable—their drive to grow without limit.

Byetta Attorneys News: More information about your search

Byetta Attorneys : Now there were two groups of genetic actors on the can­cer stage, each specifying a distinct part of the machinery that governed cell growth. The proto-oncogenes operated like the accelerator pedal in a car; mutant oncogenic versions of these genes seemed to result in pedals that were stuck to the floor. Conversely, the tumor suppressor genes worked like brakes. As normal cells developed into cancer cells, they might shed or inactivate these tumor suppressor genes, resulting in defective braking mechanisms. Runaway cell growth seemed to be explainable by either mechanism.

The existence of two diametrically opposite explanations of cancer formation demanded some resolution. Did some kinds of tumor cells rely on one mechanism to achieve ma­lignant growth while others used the alternative mechanism? Or did both mechanisms operate together within cancer cells? Perhaps stuck accelerators and faulty brakes conspired to create cancerous growth. The answers to these questions did not fall in place im­mediately. But the discovery of tumor suppressor genes did open the door to another aspect of human cancer—its heritability. Cancer often runs in families, and these genes provided an explanation for the origin of many kinds of familial cancer.

Byetta Attorneys News: Additional Information and Resources

Byetta Attorneys: But the most convenient and therefore most frequently used way for a cell to rid itself of a gene is more subtle. Most often, a gene will suffer only a single base change—a point mutation—in one of its sequences. Such a subtle change may have deadly consequences if it strikes a critical sequence in the gene. Point mutations may insert inappropriate punctua­tion marks into the middle of a gene; because these marks normally signal the end of a gene, they may terminate the read-out of the gene prematurely, causing truncation of the protein specified by this gene. Other times, the protein prod­uct of the gene may suffer some change in its string of amino acids that renders it nonfunctional. The result of all these mutations, large and small, will be the same: The cell will lose the services of the mutated gene.

In reality, losing the services of a tumor suppressor gene is more complicated than implied here. Almost all genes in our cells are present in two redundant copies, one deriving originally from our mother’s genes, the other from our father. In the case of tumor suppressor genes, this two-copy system offers a measure of protection to the cell. If one copy of a suppressor gene is accidental lost, the remaining gene copy serves as a perfectly adequate backup. Almost always, half a brake lining is as good as a whole one in slowing down cell growth.

Tumor cells usually resort to a more expedient way of eliminating the second copy of a tumor suppressor gene. Their strategy depends on the fact that the two partners in a human chromosome pair (such as the two thirteenth chromosomes, each of which carries an Rb gene copy) often line up next to one another in parallel array, look each other over, compare their respective DNA sequences, and then swap ge­netic information. One frequent result is that a gene se­quence present on one chromosome will now replace the corresponding sequence carried by its partner. Before this in­formation transfer, two distinct versions of a gene may have resided on the two paired chromosomes; afterward, one of these versions is lost, being replaced by a duplicated version of the gene originally present on the other chromosome. The result is two identical copies of a gene in a cell that previ­ously carried two dissimilar versions.

Our use of the term or terms Byetta Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Byetta Attorneys News visit our site often.

Posted in Byetta Attorneys | Tagged |